~~<i id='5063E151BE'><strike id='5063E151BE'><tt id='5063E151BE'><pre id='5063E151BE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

comprehensive

author：entertainment 2025-09-29 13:31:21 - browse：97312

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Testing GLP

focus

Wikipedia

knowledge

focus

knowledge

0:25InthisDec.2,2014filephototheRikersIslandjailcomplexisseen.SethWenig/AP,FILEAfederaljudgeshouldco

WSS

Wisconsin governor employs partial veto to fund schools for 4 centuries

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

6 surprising facts about sugar

knowledge

comprehensive

focus

Hollywood unions extend contract negotiations for actors

Wisconsin governor employs partial veto to fund schools for 4 centuries

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

Cancer drug shortages should be causing more outrage

'Patient friction coefficient' can gauge a clinical trial's patient burden

Psychedelics group wrestles with new pharma identity

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

White House announces new plan to address the growing threat of xylazine in overdose crisis

Wikipedia

White House announces new plan to address the growing threat of xylazine in overdose crisis

Readout Newsletter: Illumina, CRISPR, Regeneron

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Pregnancy ages women, but effects reverse after delivery

U.K. officials, researchers try to ease path for bespoke genetic treatments

U.K. officials, researchers try to ease path for bespoke genetic treatments

knowledge

knowledge

focus

knowledge